Author: | Chapman, P. B. |
Article Title: | Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody |
Abstract: | GD3, a ganglioside expressed on tumors of neuroectodermal origin such as melanoma and small-cell lung carcinoma (SCLC), is an attractive vaccine target but is poorly immunogenic. Our group has pursued several strategies designed to immunize patients against GD3 including using BEC2, an anti-idiotypic monoclonal antibody that mimics GD3. Pilot trials in melanoma and SCLC indicate that BEC2 can induce an anti-GD3 antibody response in a subset of patients and also suggests that immunization with BEC2 is associated with improved survival. A phase III trial is underway in SCLC patients to determine the effects BEC2 on overall survival. |
Keywords: | cancer chemotherapy; cancer survival; protein expression; unclassified drug; clinical trial; review; nonhuman; drug targeting; cancer radiotherapy; antineoplastic agent; neoplasms; animals; bcg vaccine; cancer immunotherapy; melanoma; immune system; nerve tissue proteins; antineoplastic activity; drug effect; monoclonal antibody; survival time; lung small cell cancer; pilot study; immunogenicity; antibody response; cancer immunization; vaccination; ganglioside gd3; vaccine; antibody titer; keyhole limpet hemocyanin; carcinoma, small cell; qs 21; gangliosides; bcg vaccination; neuroectoderm; gd3 ganglioside; monoclonal antibody bec2; antibodies, anti-idiotypic; ether-a-go-go potassium channels; anti-idiotype; small-cell lung carcinoma; immunotherapy, active; antiidiotypic antibody; potassium channels, voltage-gated; humans; human; potassium channels; monoclonal antibody r24; ganglioside gd3 lactone |
Journal Title: | Current Opinion in Investigational Drugs |
Volume: | 4 |
Issue: | 6 |
ISSN: | 1472-4472 |
Publisher: | Current Drugs Ltd |
Date Published: | 2003-01-01 |
Start Page: | 710 |
End Page: | 715 |
Language: | English |
PUBMED: | 12901230 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Export Date: 25 September 2014 -- Source: Scopus |